0:00
welcome back to our Channel today we're
0:02
diving into some groundbreaking news in
0:04
HIV prevention that could change the
0:06
landscape of treatment and
0:08
protection we'll explore the latest
0:10
results from the phase 3 purpose 2 trial
0:12
which shows remarkable progress in HIV
0:15
pre-exposure prophylaxis or prep we've
0:17
got a lot to cover so let's get
0:20
started recently Gilead Sciences
0:23
announced some incredible findings from
0:24
the purpose 2 trial this study examined
0:27
the effectiveness of a twice-yearly
0:28
injection of L opav a new experimental
0:31
drug designed to prevent HIV
0:34
infection Lenape is a type of antibody
0:38
that targets HIV in the body unlike
0:40
traditional medications it works by
0:43
helping the immune system fight off the
0:45
effectively in the purpose 2 trial Lop
0:49
air was tested on a diverse group of
0:51
participants including gay and bisexual
0:53
men as well as transgender and
0:55
non-binary individuals across seven
0:58
countries how it works and what it means
1:02
prevention Lenape is a novel
1:05
experimental drug designed to prevent
1:07
HIV infection it is a type of
1:09
anti-retroviral medication known as a
1:12
capsid inhibitor to understand how Len
1:14
cap ofir works it's helpful to First
1:16
grasp a few basic concepts about HIV and
1:19
the mechanisms used to combat
1:21
it HIV human imuno deficiency virus
1:25
attacks the immune system specifically
1:27
targeting CD4 cells which are crucial
1:29
for fighting off infections without
1:31
treatment HIV can lead to AIDS acquired
1:34
immuno deficiency syndrome a condition
1:36
in which the immune system is severely
1:39
compromised now how does Len capir
1:42
work Lenape is unique because it targets
1:46
a part of the HIV virus known as the
1:48
capsid the capsid is a protein shell
1:51
that surrounds and protects the viral
1:52
RNA genetic material by inhibiting the
1:55
capsid Lenape interferes with the
1:58
virus's ability to replicate and spread
2:01
body by attaching to the capsid Lop ofir
2:05
disrupts the virus's structure once
2:07
bound Lenape prevents the capsid from
2:09
performing its essential functions this
2:12
disruption blocks the virus from
2:13
releasing its RNA into host cells and
2:16
from assembling new viral
2:18
particles essentially the virus cannot
2:22
effectively by inhibiting the
2:24
replication of HIV Lenape reduces the
2:27
overall viral load in the body this
2:29
helps to lower the risk of HIV
2:31
transmission and improves the
2:33
effectiveness of the immune system's
2:38
Lenape one longlasting
2:41
Protection One of the significant
2:43
advantages of Lena air is its long
2:46
acting nature administered via an
2:48
injection every 6 months it provides
2:50
extended protection compared to daily
2:54
medications this less frequent dosing
2:56
schedule can improve adherence and make
2:58
it easier for people to stay protected
3:01
HIV two effective in multiple
3:04
populations clinical trials such as the
3:07
purpose to trial have demonstrated that
3:09
Len capir is highly effective across
3:12
various groups including gay and
3:14
bisexual men as well as transgender and
3:18
individuals three alternative to oral
3:21
prep for individuals who may struggle
3:24
with daily oral prep regimens or face
3:26
challenges related to adherence Len
3:28
pavir offers a promising alternative its
3:31
injection-based approach addresses some
3:33
of the barriers associated with daily
3:36
taking current status and future
3:39
prospects Len capir has shown great
3:42
promise in clinical trials with the
3:44
purpose to study indicating a 96%
3:47
reduction in HIV risk for those
3:49
receiving the twice-yearly injection
3:51
Gilead Sciences plans to submit data to
3:53
Regulatory Agencies to support its
3:55
approval for widespread
3:57
use if approved let aop ofir could
4:00
become a vital tool in the fight against
4:02
HIV providing an additional option for
4:04
those seeking effective prevention
4:06
methods its long acting formulation and
4:09
strong efficacy make it a potential
4:13
prevention Gilead lakap ofir's second
4:17
result the trials results are nothing
4:20
short of impressive twice yearly Len cap
4:22
ofir reduced the risk of HIV acquisition
4:26
96% this is a significant Leap Forward
4:29
compared to daily oral prep options like
4:31
Truvada which has been a staple in HIV
4:36
2012 in the purpose to study only two
4:39
new HIV infections were reported among
4:41
participants who received Len capir in
4:44
contrast nine new infections were
4:46
reported among those who took daily
4:49
pills this difference translates to an
4:51
HIV incidence rate of just 0.10 versus
4:54
2.37 per 100 person years the data
4:58
confirms that lopa is not just effective
5:02
effective Linda Gail Becker a lead
5:05
investigator from the purpose one trial
5:07
is thrilled about these results she
5:09
believes that this breakthrough will
5:11
significantly expand prevention options
5:13
for everyone including those who have
5:15
struggled with oral prep
5:17
adherence Daniel driffin an advocate
5:20
from the HIV vaccines trials Network
5:22
also expressed excitement about the
5:24
study's findings he emphasizes the
5:26
importance of ensuring that Len cap of
5:28
your prep becomes accessible to all
5:30
communities particularly marginalized
5:33
ones despite its success prep has not
5:36
yet reached its full potential according
5:38
to the CDC only about a third of those
5:40
who could benefit from prep are
5:42
currently using it this is partly
5:45
because some people have trouble with
5:46
daily pill regimens or are concerned
5:49
about the stigma associated with visible
5:52
medication lenape's twice yearly
5:54
injection could provide a game-changing
5:56
alternative by reducing the frequency of
5:59
doses IT addresses adherence issues and
6:01
offers a more convenient option for many
6:04
people principal investigator an Abu
6:07
from Yale School of Medicine highlights
6:09
that this new Option adds significantly
6:11
to our tools for HIV prevention the
6:14
long- lasting nature of Lenape could
6:16
help us move closer to an aids-free
6:19
generation lenac capir currently known
6:22
as Sun Lena for HIV treatment is poised
6:24
for a major role in prevention Gilead
6:27
plans to submit data to the FDA by the
6:29
end of the year with hopes to launch
6:31
this twice-yearly prep option in
6:34
2025 ensuring broad access is crucial
6:38
Gilead is working with various Partners
6:40
to make Len Cav year available globally
6:42
focusing on high need areas and
6:44
exploring ways to reduce
6:46
costs Advocates have raised concerns
6:49
about the cost of Len capir for
6:51
prevention given its current price for
6:53
treatment however there's optimism that
6:55
with voluntary licensing and competition
6:58
the price could become more
7:00
affordable Mitchell Warren from avak
7:03
highlights the transformative potential
7:04
of a twice-yearly injection this could
7:07
not only improve individual adherence
7:09
but also ease the burden on overextended
7:12
Systems overall the results from purpose
7:15
2 are incredibly exciting and represent
7:18
a major advancement in HIV prevention as
7:21
we look forward to broader availability
7:23
we're hopeful that these Innovations
7:25
will make a real difference in the fight
7:28
HIV if you if you found this update
7:30
helpful don't forget to like subscribe
7:32
and hit the notification Bell for more
7:33
in-depth coverage of HIV research and
7:36
treatment share your thoughts and
7:37
questions in the comments below and stay
7:39
tuned for more exciting
7:41
developments if you have not subscribed
7:44
you may not see us again so hit that
7:46
subscribe button so that you will get
7:47
notified of our next update
